REDEFINING Liquid biopsies

Revolutionizing the efficient use of NGS (Next-Generation Sequencing) in precision diagnostics

Removing the barriers for global access

Genomill is a pioneering precision diagnostics company with a mission to democratize the use of liquid biopsies for oncology, infectious disease detection and beyond, by removing the barriers for global access.

We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our proprietary Geno1® pre-sequencing platform, enabling major improvements in performance and scalability.

Our vision is to be a leader in the transformation of precision diagnostics with the ultimate goal of enabling the full potential of liquid biopsies across the world.

Low cost

High accuracy

Massive scalability

Geno1

DRIVEN BY WORLD-CLASS RESEARCH

Our proprietary and patented Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and data interpretation.

It truly provides means for vertical progress and enables fundamental improvements in cost, accuracy, turn-around-time and scalability. It unlocks the future.

JOIN OUR JOURNEY

We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1® for out-licensing and are continuously looking for new long-term collaboration partnerships within oncology and other verticals – infectious diseases, NIPT, antibiotic resistance.

Join us in harnessing a true game-changing technology!

Latest news

Genomill appoints former foundation medicine executive and plans to present unmatched data at PMWC

Genomill appoints former foundation medicine executive and plans to present unmatched data at PMWC

Seminal presentation of first analytical validation data scheduled for june 30
<font color="#4B9CD2"> Genomeweb: </font> Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

 NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming…
Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive…